Guideline / position statementindependent cross-checkfull text checked★ key study I-GUT-108 in-depth review
UK guideline on heartburn and indigestion
Gastro-oesophageal reflux disease and dyspepsia in adults: investigation and management (NICE guideline CG184)
Overview
National Institute for Health and Care Excellence (NICE). NICE guideline CG184 2014 (last updated 18 October 2019)
NICE advises lifestyle changes and the lowest effective dose of acid blockers, but long-term full-dose treatment for severe inflammation or a narrowed gullet.
Does the study support the specific claim? Partly · Methodological quality: high
Plain-language summary
Study explained simply
- What did the researchers want to find out?
Guide care of reflux and indigestion.
- How was the study done?
National guideline.
- How many people, animals or samples were studied?
Adults in England.
- What was actually found?
Lifestyle first; step down PPIs; keep PPIs for stricture/severe oesophagitis; eradicate H. pylori in ulcers.
- How large was the observed effect?
Not applicable.
- What do the results mean in everyday life?
Diet matters, but some people need acid blockers long term.
- What are the study's limitations?
Older evidence base for some statements.
- What does it say about Elawady's specific claim?
Contradicts a blanket ban on acid blockers.
- Do the results apply to Germany and Europe?
Applies directly to Europe.
- What can explicitly not be concluded from this study?
Not an evidence synthesis for each claim.
Scientific in-depth review
1. Full reference
- Authors
- National Institute for Health and Care Excellence (NICE)
- Journal
- NICE guideline CG184
- Year
- 2014 (last updated 18 October 2019)
- Identifier
- Verification
- verified – Fetched URL 2026-10-26 (HTTP 200, page text read)
- Retracted
- no
- Corrections
- none
- Extent checked
- full text
- Conflicts of interest and funding
NICE (public body)
2. Research question
How should adults with dyspepsia and GORD be investigated and managed?
3. Study design and population
- Study design
- Guideline / position statement – National clinical guideline (recommendations page)
- Population
Adults with dyspepsia, GORD or both
- Country
UK (England)
- Period
Published 2014; updated 2019
- Sample size
Not applicable
- Inclusion and exclusion criteria
Not applicable
4. Methods and endpoints
- Exposure / intervention
PPI, H2RA, lifestyle advice, H. pylori eradication, endoscopy
- Comparator
Not applicable
- Endpoints
Clinical recommendations
- Statistical methods
Not applicable
5. Actual results
- Results
1.2.1-1.2.2: offer lifestyle advice (healthy eating, weight reduction, smoking cessation); avoid personal precipitants (smoking, alcohol, coffee, chocolate, fatty foods, overweight); raise the head of the bed and have the main meal well before bed. 1.2.5/1.4.5: step down PPI to the lowest effective dose or as-needed use unless an underlying condition needs continuing treatment. 1.3.1: dyspepsia with significant acute GI bleeding - same-day specialist referral. 1.6.6: after dilatation of an oesophageal stricture remain on long-term full-dose PPI. 1.6.9: offer full-dose PPI long-term as maintenance for severe oesophagitis. 1.7.1: offer H. pylori eradication to H. pylori-positive people with peptic ulcer. 1.7.7: in high-risk people needing NSAIDs, prescribe with a PPI.
- Absolute risks
Not applicable
- Authors' conclusion
Lifestyle advice first; lowest effective PPI dose; long-term PPI for stricture and severe oesophagitis; eradicate H. pylori in ulcer disease.
6. Strengths
- Official national guideline
- Explicit recommendations
- Page text read in full
7. Weaknesses
- Core recommendations from 2004/2014
- Not specific to Egypt
8. Risk of bias
- Orienting tool
- none applicable
- Type of assessment
- simplified assessment (abstract only)
- Full formal assessment
- no
- Overall risk of bias
- not assessable
- Rationale
Guideline; AGREE II not applied.
9. Assessment of the statistical interpretation
Not applicable
10. Relevance to the specific claim
Shows both sides: diet and lifestyle are first-line and PPIs should be stepped down, but some conditions require long-term PPI and bleeding needs urgent care.
11. Independent contrary findings
None for the cited statements.
12. Transferability to Germany and Europe
Directly applicable to Europe; principles apply in Egypt.
13. Overall methodological judgement
Authoritative guideline that contradicts a universal PPI ban and supports diet/lifestyle advice.
| Multidimensional assessment | |
|---|---|
| Authenticity of the source | verified |
| Methodological quality | high |
| Risk of bias | not assessable |
| Precision of results | not applicable |
| Directness | direct |
| Reproducibility | unknown |
| Consistency with the overall evidence | consistent |
| Regional transferability | high |
| Adequacy of the interpretation (by the archive) | not applicable |
14. Open questions
None.
15. Linked fact checks
- All acid-suppressing medicines (PPIs and H2 blockers) are permanently forbidden; heartburn should stop through the diet, not through drugs. – Studies contradicting or limiting the claim
- Stopping bread and baked goods for five days will improve 85% of reflux and IBS symptoms within at most ten days; both diseases can be eliminated completely. – Studies contradicting or limiting the claim
- Redefining peptic ulcer as an H. pylori infection was a 'crime'; the real problem is low stomach acid, and acid blockers plus antibiotic 'triple therapy' are the wrong treatment. – Studies contradicting or limiting the claim
- Sleeping or lying down directly after eating is no problem at all; the body is built to eat and drink lying on the side or back. – Studies contradicting or limiting the claim
- PPIs are widely prescribed without a real indication (for example by doctors of other specialties to 'protect the stomach') and are now sold freely. – Studies supporting the claim